http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2537128-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd569fbfa1953ca9b7b375510e4d2763 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-738 |
| filingDate | 2010-08-13^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c135db8b1c8fa68182fe162365d1adf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a32bd18786c320b4bb874052f22ae20a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0874360170740b1ebe50cf9e14a29173 |
| publicationDate | 2015-06-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2537128-T3 |
| titleOfInvention | Pharmaceutical composition to suppress pain |
| abstract | Pharmaceutical composition for use in the relief of pain in a human joint disease, comprising: a hyaluronic acid that is crosslinked by cyclization of a double bond in a residue of a cinnamic acid in a partially amidated hyaluronic acid represented by the formula (1 ), to form a cyclobutane ring, [Ar-CH> = CH-COO- (CH2) n-NH-] m-HA (1) in which Ar represents an optionally substituted phenyl group, n represents an integer number of 2 or 3, HA represents a carboxyl residue of hyaluronic acid, and m represents the ratio of amidation of hyaluronic acid with respect to the total carboxyl group and is from 3% to 50% in relation to the total carboxyl group; and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is a product for injection, in which an individual dosage of the product for injection is 2 to 3 ml; and wherein the pharmaceutical composition is an individual dose preparation, and is administered in an administration range of 13 weeks or more. |
| priorityDate | 2009-08-13^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 60 of 60.